Background

The human genome contains ∼21,000 distinct protein-coding genes, out of which ∼5,360 code for membrane proteins. Membrane proteins are critical for many cellular processes, such as signaling transduction, ion transportation, pathogen interaction, and 60% of drugs currently in the market target membrane proteins. The antibody off-target identification and specificity profiling service is the leading solution for antibody and CAR-T specificity profiling using membrane proteome array technology. This cell-based array contains more than 6000 human membrane proteins assembled to determine the specificity of antibodies, CAR-T cell therapies, and other biotherapeutics. By testing antibodies or chimeric antigen receptor (CAR) T cells against an array of native proteins, you know exactly what specificity you are getting.

Services

Antibody Off-target Identification and Specificity Profiling Service
using the membrane protein library, flow cytometry, and unfixed cells for detection.

Antibody Off-target Identification and Specificity Profiling Service
making your projects successful.

Antibody Off-target Identification and Specificity Profiling Service

With years of experience in membrane proteins production, Creative Biolabs is dedicated to offering antibody off-target identification and specificity profiling service to determine the specificity of antibodies, CAR-T cell therapies, and other biotherapeutics using membrane proteome array technology. Our strategies of antibody off-target identification and specificity profiling service include 3 main steps: 1) optimize conditions for detecting antibody binding; 2) high throughput screening; 3) confirm all identified targets in a second flow cytometry titration experiment. Please contact us for more detailed information to know how we can help.

Fig.1 Antibody Off-target Identification and Specificity Profiling Service Workflow. (Gerhart, 2020)

Antibody Off-target Identification and Specificity Profiling Application

• Assess specificity and off-target binding of antibodies and protein ligands

The screening service was validated by testing the specificity of antibodies with known membrane protein targets. The antibody against an ion channel (anti-P2X3) was tested. The known target for each anti-P2X3 antibody was readily identified. The service also identified binding to an additional membrane protein, informing the final lead selection in this program to avoid off-target binding that could cause patient side effects.

Fig.2 Assess specificity and off-target binding of antibodies. (Huston-Paterson, 2016)

• Specificity identification and off-target binding of CAR-T

High throughput membrane proteome array screening identified off-target CAR-T cells. More than 6000 membrane proteins were expressed in HEK293T and QT6 cells and then screened with soluble Fc-tagged proteins to assess binding.

Fig.3 Specificity identification and off-target binding of CAR-T. (Lee, 2020)

• Functional screening for new viral receptors

The systematic array of the membrane proteome in live human cells provides a unique opportunity to test the function of each membrane protein in live cell-based assays, such as the identification of novel receptors for Zika and Ebola viruses.

Fig.4 High throughput membrane proteome array screening for pathogen receptor discovery. (Huston-Paterson, 2016)

Frequently Asked Questions

Q: What does the array contain?
A: Antibody off-target identification and specificity profiling service contains more than 6000 human membrane proteins natively expressed in human cells.

Q: What's cells expressed membrane proteins?
A: Membrane proteins were expressed in unfixed human cells including HEK293 cells and Avian QT6 cells.

Q: What are the deliverables that I will receive?
A: You will receive a detailed report containing the binding profiles of your antibodies/ligands/CAR-T and validation results on identified targets.

References

1. Tan, Y.; et al. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. Blood Cancer J. 2021, 11(4):71.
2. Gerhart, J.; et al. Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage. PLoS ONE, 2020, 15(7):e0234792.
3. Huston-Paterson, D.J.; et al. Screening the Membrane Protein: A High-Throughput Platform for Identifying Membrane Protein Antibody Targets. Genetic engineering & biotechnology news. 2016, 36(15):18-19.
4. Lee, J.; et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. The Journal of clinical investigation. 2020, 130(12):6317-6324.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.